Pharmacoeconomic evaluation for peripheral T-cell lymphoma:a systematic review
Objective:To systematically review the pharmacoeconomic evaluation of peripheral T-cell lymphoma(PTCL)and summarize and analyze model settings and other methodological points,thus to provide reference for pharmacoeconomic evaluation of PTCL-related interventions in the future.Methods:PubMed,Web of Science,The Cochrane Library,CNKI,WanFang Data,and VIP were electronically searched to collect relevant literature on the PTCL pharmacoeconomic evaluation from the inception of the database to April 2023.Two researchers independently screened literature,extracted key information from pharmacoeconomic evaluation,and appraised the quality of included studies by Consolidated Health Economic Evaluation Reporting Standards.Results:A total of 13 studies with an average score of 84.07%for quality assessment were included,indicating that the overall quality was good.Twelve studies(92.3%)used cost-utility analysis,11 studies(84.6%)mainly used partitioned survival model over a lifetime horizon,and included stem cell transplantation in their models.The survival data were mostly extrapolated by using standard parametric models(92.3%)or mixed cure models(15.4%).The cost was dominated by direct medical costs,and 6 studies(46.2%)additionally considered the negative effects of adverse events.The results of 12 studies(92.3%)showed that the new drug interventions in the research had economic advantages compared with standard therapy.Conclusion:There were some differences among the included studies in the settings of stem cell transplantation,the use of indirect comparison methods,and the use of survival curve fitting extrapolation methods.
NETL
NSTL
万方数据
